<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-beats-quarterly-estimates-eczema-drug-strength-shares-rise-2026-07-30/">Regeneron übertrifft Quartalsschätzungen dank Stärke beim Ekzem-Medikament, Aktien steigen</a>
    </div>

      <div class="me-0 me-md-5">
        Regeneron übertraf am Donnerstag die Gewinn- und Umsatzschätzungen der Wall Street für das zweite Quartal, gestützt durch eine starke Nachfrage nach seinem Ekzem-Medikament Dupixent und einer hochdosierten Version seines Augenmedikaments Eylea.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/07/30/3335868/0/en/Regeneron-Reports-Second-Quarter-2026-Financial-and-Operating-Results.html">Regeneron legt Finanz- und Betriebsergebnisse für das zweite Quartal 2026 vor</a>
    </div>

      <div class="me-0 me-md-5">
        TARRYTOWN, N.Y., 30. Juli 2026 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) gab heute die Finanzergebnisse für das zweite Quartal 2026 bekannt und bot ein Geschäftsupdate.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">WSJ</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.wsj.com/health/pharma/regeneron-george-yancopoulos-drug-discovery-17fea3fa">Der Wissenschaftler mit 1.000 Patenten, der ein Arzneimittel-Imperium antreibt</a>
    </div>

      <div class="me-0 me-md-5">
        Bei Regeneron ist George Yancopoulos der seltene Wissenschaftler und Manager, der Wachstum durch Entdeckungen statt durch Übernahmen vorantreibt.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Barrons</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.barrons.com/articles/booking-holdings-alphabet-stocks-buy-ahead-of-earnings-4983aa52">Booking, Alphabet und 7 weitere Aktien, die man vor den Quartalszahlen kaufen sollte</a>
    </div>

      <div class="me-0 me-md-5">
        Booking Holdings, Alphabet und sechs weitere Unternehmen haben sich gegenüber ihren Branchen unterdurchschnittlich entwickelt, obwohl sich die Gewinnerwartungen verbessert haben, und bieten damit potenzielles Aufwärtspotenzial während der Berichtssaison für das zweite Quartal.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/fda-selects-lilly-regeneron-program-speed-up-review-new-manufacturing-facilities-2026-06-29/">FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports</a>
    </div>

      <div class="me-0 me-md-5">
        The U.S. ​Food and ‌Drug Administration has ​selected Eli ​Lilly and Regeneron , ⁠among ​seven companies, ​for a pilot program ​to ​accelerate reviews of ‌new ⁠domestic pharmaceutical manufacturing facilities, CNBC ​reported ​on ⁠Monday citing ​an ​FDA ⁠spokesperson.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">CNBC</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.cnbc.com/2026/06/29/eli-lilly-regeneron-in-fda-precheck-manufacturing-program.html">Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities</a>
    </div>

      <div class="me-0 me-md-5">
        Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA&#39;s PreCheck pilot program. The FDA PreCheck program is designed to accelerate regulatory review of new pharmaceutical manufacturing facilities.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/22/3315167/0/en/Cemdisiran-Regulatory-Submissions-Accepted-for-Review-by-FDA-and-EMA-for-the-Treatment-of-Generalized-Myasthenia-Gravis-gMG.html">Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)</a>
    </div>

      <div class="me-0 me-md-5">
        Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/04/3306640/0/en/regeneron-to-highlight-progress-across-its-metabolic-disease-ophthalmology-and-rare-disease-pipelines-at-ada-and-endo.html">Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO</a>
    </div>

      <div class="me-0 me-md-5">
        TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare disease pipelines will be presented at two major medical meetings in June 2026.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Regeneron-Pharmaceuticals-US75886F1075/load_more?page=5">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>